Neeraj Singh, MD
Nephrology · New Brunswick, NJNPI 1093919920
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 49.8% of the total. Reporting peaked in 2019 at $36,036 and has fallen 67.0% since, to $11,877 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $535.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$66K
- Veloxis Pharmaceuticals, Inc.$39K
- Mallinckrodt Enterprises LLC$15K
- Vifor Pharma, Inc.$5K
- Vertex$4K
- Travere Therapeutics, Inc.$1K
- plus $3K from 24 others
What the payments were for
- Consulting fees$23,40018%
- Speaking & faculty fees$77,67358%
- Travel & lodging$22,72917%
- Food & beverage$8,4376%
- Education$2890%
- Gifts$410%
- Entertainment$2430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 74 | $66,141 |
| Veloxis Pharmaceuticals, Inc. | 46 | $38,906 |
| Mallinckrodt Enterprises LLC | 28 | $14,575 |
| Vifor Pharma, Inc. | 9 | $5,029 |
| Vertex | 1 | $3,575 |
| Travere Therapeutics, Inc. | 10 | $1,215 |
| AstraZeneca(2 entities) | 32 | $760 |
| Calliditas Therapeutics US Inc. | 4 | $464 |
| La Jolla Pharmaceutical Company | 3 | $323 |
| Melinta Therapeutics, LLC | 5 | $302 |
| Eurofins Viracor, LLC | 4 | $243 |
| Amgen(2 entities) | 4 | $153 |
| Sanofi-aventis U.S. LLC | 1 | $150 |
| Insmed, Inc. | 1 | $128 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $124 |
| Merck | 5 | $109 |
| Novartis | 2 | $101 |
| E.r. Squibb & Sons, L.L.C. | 2 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $47 |
| Dova Pharmaceuticals | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| GSK | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Conmed Corporation | 1 | $17 |
| Medtronic | 1 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,812 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 139 | $38,797 |
| LokelmaSodium Zirconium Cyclosilicate | 36 | $36,776 |
| VeltassaPatiromer Calcium Sorbitex | 29 | $35,680 |
| Valganciclovir Hcl | 84 | $25,715 |
| Tacrolimus | 27 | $4,938 |
| Nifedipine ErNifedipine | 248 | $3,376 |
| Bumetanide | 116 | $2,606 |
| Pantoprazole Sodium | 394 | $2,237 |
| Mycophenolate Mofetil | 34 | $2,072 |
| Carvedilol | 263 | $1,805 |
| Prednisone | 385 | $1,456 |
| Sevelamer Carbonate | 12 | $1,169 |
| Calcitriol | 51 | $1,110 |
| Leflunomide | 26 | $1,022 |
| Hydralazine Hcl | 118 | $808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma | $760 | $36,77636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.
Other nephrology in New Brunswick
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
- Joseph AlbaneseBrick$41K
- Louis JanEnglewood$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.